FIELD: chemistry.
SUBSTANCE: invention relates to a solid form of the compound of formula I-2, wherein the form is selected from the group consisting of crystalline free base of compound I-2, characterized by peaks expressed in 2-theta ±0.2 at about 14.2, 25.6, 18.1, 22.0 and 11.1 degrees in a X-ray powder diffraction pattern obtained using Cu K alpha radiation, or crystalline compound I-2 • HCl, characterized by peaks expressed in 2-theta ±0.2 at about 13.5, 28.8, 15.0, 18.8 and 15.4 degrees in a X-ray powder diffraction pattern obtained when using Cu K alpha radiation.
I-2.
EFFECT: according to the invention the compound of formula I-2 has the ability to inhibit ATR kinase and is used for the production of a medicament for treating pancreatic cancer or non-small cell lung cancer, and is also stable.
18 cl, 20 dwg, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BORON-CONTAINING SMALL MOLECULES | 2006 |
|
RU2606947C2 |
| BORON-CONTAINING SMALL MOLLECULES | 2006 |
|
RU2414906C2 |
| HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | 2012 |
|
RU2648997C2 |
| CFTR REGULATORS AND METHODS OF USING | 2016 |
|
RU2730855C2 |
| MMPL3 INHIBITORS, COMPOSITIONS BASED ON THEM AND WAYS OF THEIR APPLICATION | 2019 |
|
RU2795229C2 |
| 6-MEMBERED HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2016 |
|
RU2683245C1 |
| MACROCYCLIC HEPATITIS TYPE C VIRUS INHIBITORS | 2006 |
|
RU2419619C2 |
| INTERMEDIATE CHEMICAL COMPOUND | 2003 |
|
RU2326122C2 |
| AGONIST OF THE GLUCOCORTICOID RECEPTOR AND ITS IMMUNOCONJUGATES | 2017 |
|
RU2745748C2 |
| β-D-2ʹ-DEOXY-2ʹ-α-FLUORO-2ʹ-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR TREATMENT OF DISEASES CAUSED BY HCV | 2016 |
|
RU2764767C2 |
